{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:34:39Z","timestamp":1784896479282,"version":"3.55.0"},"reference-count":87,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Chimeric antigen receptor T therapy has heralded a new era in the treatment of acute lymphoblastic leukemia (ALL) and other hematologic malignancies. In this autologous immunotherapy, patient-derived T cells are genetically engineered and then infused back to kill the leukemia cells. The observed response rates in ALL are a testament to the success of this therapy. However, there have been instances where the patients either did not respond or relapsed after initial response. Emergence of resistance due to antigen loss and T-cell exhaustion has been observed. This poses a challenge in making this therapy successful for every ALL patient and warrants deeper understanding of emergence of resistance and potential approaches to overcome them. Here we discuss current perspectives and advances in this area.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000513","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T07:14:18Z","timestamp":1616224458000},"page":"151-158","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Improving and Maintaining Responses in Pediatric B\u2013Cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptor\u2013T Cell Therapy"],"prefix":"10.1097","volume":"27","author":[{"given":"Rahul","family":"Arya","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Oncology, The Children's Hospital of Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Barrett","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Oncology, The Children's Hospital of Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Oncology, The Children's Hospital of Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Joseph","family":"Melenhorst","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20250621","first-page":"40","article-title":"Acute lymphoblastic leukemia","volume":"32","year":"2002","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"2040620720927575","DOI":"10.1177\/2040620720927575","article-title":"Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia","volume":"11","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1016\/S2352-3026(17)30052-2","article-title":"Worldwide comparison of survival from childhood leukaemia for 1995\u20132009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries","volume":"4","year":"2017","journal-title":"Lancet Haematol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031","volume":"28","year":"2014","journal-title":"Leukemia"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","article-title":"Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children's Oncology Group trial AALL0622","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-18-2337","article-title":"FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease","volume":"25","year":"2019","journal-title":"Clin Cancer Res"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1470-2045(08)70229-8","article-title":"Bone-marrow relapse in paediatric acute lymphoblastic leukaemia","volume":"9","year":"2008","journal-title":"Lancet Oncol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1182\/blood.V91.5.1716.1716_1716_1722","article-title":"TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Munster Study Group","volume":"91","year":"1998","journal-title":"Blood"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/s41375-018-0094-0","article-title":"Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study","volume":"32","year":"2018","journal-title":"Leukemia"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","year":"2010","journal-title":"Blood"},{"key":"bib12-20250621","first-page":"95ra73","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","year":"2011","journal-title":"Sci Transl Med"},{"key":"bib13-20250621","first-page":"177ra38","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","year":"2013","journal-title":"Sci Transl Med"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-med-060512-150254","article-title":"Chimeric antigen receptor therapy for cancer","volume":"65","year":"2014","journal-title":"Annu Rev Med"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jamapediatrics.2018.2530","article-title":"Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia","volume":"172","year":"2018","journal-title":"JAMA Pediatr"},{"key":"bib21-20250621","first-page":"JCO2002477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","year":"2021","journal-title":"J Clin Oncol"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","year":"2015","journal-title":"Cancer Discov"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","year":"2018","journal-title":"Nat Med"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","year":"2018","journal-title":"Nat Med"},{"key":"bib25-20250621","first-page":"e00383","article-title":"CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum","volume":"38","year":"2018","journal-title":"Mol Cell Biol"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s41375-019-0580-z","article-title":"Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19","volume":"34","year":"2020","journal-title":"Leukemia"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11864-016-0406-4","article-title":"CAR T cell therapy in acute lymphoblastic leukemia and potential for chronic lymphocytic leukemia","volume":"17","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"e96976","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","year":"2018","journal-title":"JCI Insight"},{"key":"bib29-20250621","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","year":"2016","journal-title":"Nat Commun"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1038\/bcj.2017.89","article-title":"Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A\/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis","volume":"7","year":"2017","journal-title":"Blood Cancer J"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","article-title":"Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction","volume":"10","year":"2020","journal-title":"Cancer Discov"},{"key":"bib34-20250621","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"bib35-20250621","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","year":"2016","journal-title":"Immunity"},{"key":"bib36-20250621","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","year":"2019","journal-title":"Nat Med"},{"key":"bib37-20250621","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","year":"2019","journal-title":"Leukemia"},{"key":"bib38-20250621","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hon.2672","article-title":"Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor\u2013modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia","volume":"37","year":"2019","journal-title":"Hematol Oncol"},{"key":"bib39-20250621","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","year":"2019","journal-title":"J Clin Invest"},{"key":"bib40-20250621","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"bib41-20250621","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic Leukemia","volume":"24","year":"2018","journal-title":"Clin Cancer Res"},{"key":"bib42-20250621","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1158\/1078-0432.CCR-19-1339","article-title":"Sustained therapeutic efficacy of humanized anti-CD19 chimeric antigen receptor T cells in relapsed\/refractory acute lymphoblastic leukemia","volume":"26","year":"2020","journal-title":"Clin Cancer Res"},{"key":"bib43-20250621","doi-asserted-by":"crossref","first-page":"102931","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: elements and their synergistic function","volume":"58","year":"2020","journal-title":"EBioMedicine"},{"key":"bib44-20250621","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ccell.2019.12.014","article-title":"THEMIS-SHP1 recruitment by 4-1BB tunes LCK-mediated priming of chimeric antigen receptor\u2013redirected T cells","volume":"37","year":"2020","journal-title":"Cancer Cell"},{"key":"bib45-20250621","doi-asserted-by":"crossref","first-page":"e99048","DOI":"10.1172\/jci.insight.99048","article-title":"Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity","volume":"3","year":"2018","journal-title":"JCI Insight"},{"key":"bib46-20250621","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/bjh.15812","article-title":"Phenotype switch in acute lymphoblastic leukaemia associated with 3 years of persistent CAR T cell directed-CD19 selective pressure","volume":"186","year":"2019","journal-title":"Br J Haematol"},{"key":"bib47-20250621","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/sj.leu.2405005","article-title":"Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3\/ITD","volume":"22","year":"2008","journal-title":"Leukemia"},{"key":"bib48-20250621","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","year":"2019","journal-title":"Blood Adv"},{"key":"bib49-20250621","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","year":"2018","journal-title":"Nat Med"},{"key":"bib50-20250621","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","year":"2018","journal-title":"Nature"},{"key":"bib51-20250621","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","article-title":"Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy","volume":"3","year":"2019","journal-title":"Blood Adv"},{"key":"bib52-20250621","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nri3839","article-title":"Perforin and granzymes: function, dysfunction and human pathology","volume":"15","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"bib53-20250621","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41577-018-0009-3","article-title":"An early history of T cell\u2013mediated cytotoxicity","volume":"18","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"bib54-20250621","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","year":"2019","journal-title":"Int J Mol Sci"},{"key":"bib55-20250621","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1134\/S0006297920020017","article-title":"Granzymes and mitochondria","volume":"85","year":"2020","journal-title":"Biochemistry (Mosc)"},{"key":"bib56-20250621","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","article-title":"Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase","volume":"25","year":"2017","journal-title":"Mol Ther"},{"key":"bib57-20250621","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4049\/jimmunol.1402346","article-title":"Target antigen density governs the efficacy of anti\u2013CD20-CD28-CD3 \u03b6 chimeric antigen receptor\u2013modified effector CD8+ T cells","volume":"194","year":"2015","journal-title":"J Immunol"},{"key":"bib58-20250621","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/mt.2016.82","article-title":"Superior therapeutic index in lymphoma therapy: CD30(+) CD34(+) hematopoietic stem cells resist a chimeric antigen receptor T-cell attack","volume":"24","year":"2016","journal-title":"Mol Ther"},{"key":"bib59-20250621","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape","volume":"126","year":"2016","journal-title":"J Clin Invest"},{"key":"bib60-20250621","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-18-3784","article-title":"Modulation of target antigen density improves CAR T-cell functionality and persistence","volume":"25","year":"2019","journal-title":"Clin Cancer Res"},{"key":"bib61-20250621","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib62-20250621","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"bib63-20250621","first-page":"301","article-title":"CXCL12\/SDF-1 and CXCR4","volume":"6","year":"2015","journal-title":"Front Immunol"},{"key":"bib64-20250621","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.exphem.2006.04.002","article-title":"Mutual, reciprocal SDF-1\/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD\/SCID chimeric mice","volume":"34","year":"2006","journal-title":"Exp Hematol"},{"key":"bib65-20250621","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","year":"2018","journal-title":"Nat Med"},{"key":"bib66-20250621","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","year":"2015","journal-title":"Cancer Cell"},{"key":"bib67-20250621","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00894-008-0334-8","article-title":"Molecular docking guided 3D-QSAR CoMFA analysis of N-4-pyrimidinyl-1H-indazol-4-amine inhibitors of leukocyte-specific protein tyrosine kinase","volume":"14","year":"2008","journal-title":"J Mol Model"},{"key":"bib68-20250621","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1172\/JCI133215","article-title":"Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability","volume":"130","year":"2020","journal-title":"J Clin Invest"},{"key":"bib69-20250621","doi-asserted-by":"crossref","first-page":"eaag1209","DOI":"10.1126\/scitranslmed.aag1209","article-title":"TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance","volume":"9","year":"2017","journal-title":"Sci Transl Med"},{"key":"bib70-20250621","doi-asserted-by":"crossref","first-page":"15040","DOI":"10.1038\/celldisc.2015.40","article-title":"Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA","volume":"1","year":"2015","journal-title":"Cell Discov"},{"key":"bib71-20250621","first-page":"224ra25","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","year":"2014","journal-title":"Sci Transl Med"},{"key":"bib72-20250621","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib73-20250621","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"bib74-20250621","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","year":"2016","journal-title":"Cancer Discov"},{"key":"bib75-20250621","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib76-20250621","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"bib77-20250621","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib78-20250621","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell\u2013engaging therapies","volume":"20","year":"2014","journal-title":"Cancer J"},{"key":"bib79-20250621","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ijc.20270","article-title":"CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice","volume":"111","year":"2004","journal-title":"Int J Cancer"},{"key":"bib80-20250621","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","article-title":"Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family","volume":"5","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"bib81-20250621","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1158\/1078-0432.CCR-20-1434","article-title":"Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"26","year":"2020","journal-title":"Clin Cancer Res"},{"key":"bib82-20250621","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery","volume":"26","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib83-20250621","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1172\/JCI138473","article-title":"Sleeping Beauty\u2013engineered CAR T cells achieve antileukemic activity without severe toxicities","volume":"130","year":"2020","journal-title":"J Clin Invest"},{"key":"bib84-20250621","first-page":"177","article-title":"Tisagenlecleucel (Kymriah) for ALL","volume":"59","year":"2017","journal-title":"Med Lett Drugs Ther"},{"key":"bib85-20250621","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1080\/14737140.2018.1512411","article-title":"Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia","volume":"18","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"bib86-20250621","first-page":"e122","article-title":"Axicabtagene ciloleucel (Yescarta) for B-cell lymphoma","volume":"60","year":"2018","journal-title":"Med Lett Drugs Ther"},{"key":"bib87-20250621","first-page":"e38","article-title":"Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy","volume":"192","year":"2020","journal-title":"Br J Haematol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T17:04:15Z","timestamp":1750525455000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000513","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}